Prosecution Insights
Prosecution Insights
3 pending office actions • 0 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Nippon Medical School Foundation is currently managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 pending office actions are being handled by 4 distinct examiners, yet all of them are concentrated within 1 distinct art unit. This structure indicates that while the company is dealing with several different individuals, the procedural environment is centralized within a single organizational group at the patent office.
TIWARI, VYOMA SHUBHAM is the busiest examiner for the portfolio, with 1 pending office action currently active. Because there are 4 distinct examiners for the 4 pending office actions, each matter is receiving a unique individual review. However, the fact that all 4 distinct examiners operate within 1 distinct art unit suggests that the company can expect a consistent application of art unit policies and technical standards across its Biotechnology & Pharmaceuticals filings. This combination of 4 distinct examiners and 1 distinct art unit requires the foundation to tailor its arguments to four different people while adhering to the specific guidelines of a single administrative unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIWARI, VYOMA SHUBHAM | 1 | 31.5% | +48.1% |
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18839277 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | TIWARI, VYOMA SHUBHAM | — |
| 18838888 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | SALVOZA, M FRANCO G | — |
| 18726183 | FUNCTIONAL FOOD CONTAINING BONITO-DERIVED EXTRACT FOR PREVENTING OR AMELIORATING NEUROPSYCHIATRIC DISORDERS | AFREMOVA, VERA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18839277 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | TIWARI, VYOMA SHUBHAM | — |
| 18838888 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | SALVOZA, M FRANCO G | — |
| 18726183 | FUNCTIONAL FOOD CONTAINING BONITO-DERIVED EXTRACT FOR PREVENTING OR AMELIORATING NEUROPSYCHIATRIC DISORDERS | AFREMOVA, VERA | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839277 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | TIWARI, VYOMA SHUBHAM | — | §102§112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18838888 | AGENT FOR ENHANCING PRODUCTION OF VIRAL VECTOR AND METHOD FOR PRODUCING VIRAL VECTOR | SALVOZA, M FRANCO G | — | §101§102§112 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18726183 | FUNCTIONAL FOOD CONTAINING BONITO-DERIVED EXTRACT FOR PREVENTING OR AMELIORATING NEUROPSYCHIATRIC DISORDERS | AFREMOVA, VERA | — | §101§102§103 | Final Rejection | — | Pending | Jul 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial